Recent Updates — LH

Labcorp Holdings Inc. reported third-quarter 2026 revenue of $3.81 billion, a 6.9% increase from the prior year period, and diluted earnings per share of $3.22. The company raised its full-year adjusted EPS guidance to a range of $18.30 to $18.70, up 18 cents at the midpoint, citing strong performance in specialty testing and margin expansion. Labcorp also announced four M&A transactions expected to be accretive to earnings and received FDA approval for a companion diagnostic for advanced melanoma. The global leader of innovative and comprehensive laboratory services provides diagnostics and drug development support.

The Board of Directors declared a quarterly cash dividend of $0.72 per share of common stock. The payment is scheduled for December 11, 2026, to shareholders of record as of the close of business on November 24, 2026. Labcorp Holdings Inc. operates in the laboratory services industry, providing comprehensive diagnostics and drug development capabilities.

Labcorp Holdings Inc. disclosed that the Centers for Medicare & Medicaid Services released preliminary Clinical Laboratory Fee Schedule payment rates for 2027 through 2029 under PAMA. The company stated these rates are based on unrepresentative data and impose steep annual cuts threatening patient access, prompting continued support for the RESULTS Act. Labcorp reaffirmed its long-term outlook announced September 10, 2026: compound annual revenue growth of 5% to 8%, adjusted operating margin expansion of 75 to 150 basis points by end-2029, and adjusted EPS growth of 8.5% to 11.5%. The company expects to assess the CMS rates' impact on 2027 guidance in February 2027. Labcorp Holdings Inc. operates in the diagnostic laboratory services industry.

Labcorp Holdings Inc. hosted its 2026 Investor Day on September 10, 2026, reaffirming full-year 2026 guidance and providing a long-term financial outlook through 2029. The company expects compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. For 2026, Labcorp projects enterprise revenue between $14.71 billion and $14.83 billion, with adjusted earnings per share ranging from $18.10 to $18.55. The firm outlined strategic priorities focused on specialty testing in oncology, neurology, autoimmune diseases, and women’s health, alongside investments in artificial intelligence and robotics. Labcorp operates as a global leader of innovative and comprehensive laboratory services.